Lerche, Holger http://orcid.org/0000-0002-1783-8710
Article History
First Online: 6 October 2020
Competing interests
: H.L. has received personal honoraria for consulting or speaking from Arvelle, Bial, Biomarin, Desitin, Eisai and UCB; travel support from Bial, Desitin, Eisai and UCB; and research support from Bial, none directly related to any of the work presented here. He is a clinical investigator of the eslicarbazepine acetate trial (EudraCT Number: 2018-002747-29).